Related Experiment Video
Updated: May 15, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
[New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept]
1Dept. of Clinical Oncology, Tohoku University, Japan.
Abstract:
Since the approval of bevacizumab, cetuximab, and panitumumab, development of novel molecular-targeted agents for colorectal cancer has been awaited. Recent phase III trials revealed that new molecular-target agents, regorafenib and aflibercept, are useful for previously treated mCRC. Regorafenib is an oral multi-kinase inhibitor which targets angiogenic, stromal and oncogenic receptor tyrosine kinase(RTK). Aflibercept is a recombinant fusion protein that consists of vascular endothelial growth factor(VEGF)-binding portions from the extracellular domains of human VEGF receptors 1 and 2, fused to the Fc portion of the human IgG1 immunoglobulin. They are different in structure, but an anti-angiogenic effect is one of the main mechanisms of action they have in common. Consistent with the 18147ML study, bevacizumab beyond progression (BBP), anti-angiogenic therapies are important in any line of chemotherapy for colorectal cancer.
Insights
New molecular-targeted agents like regorafenib and aflibercept show promise for previously treated metastatic colorectal cancer (mCRC). Anti-angiogenic therapies are crucial in chemotherapy for colorectal cancer.
Area of Science:
- Oncology
- Pharmacology
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Treatment Resistent Cancers
Pharmacogenomics: Identification of New Drug Targets

